Unsymmetrical cyclic ureas as HIV-1 protease inhibitors: Novel biaryl indazoles as P2/P2' substituents

Bioorganic and Medicinal Chemistry Letters

Volumn 9, Issue 22, 1999, Pages 3217-3220

  Patel, Mona ^a   Rodgers, James D ^a   McHugh Jr , Robert J ^a   Johnson, Barry L ^a   Cordova, Beverly C ^a   Klabe, Ronald M ^a   Bacheler, Lee T ^a   Erickson Viitanen, Susan ^a   Soo S, Ko ^a  

^a DUPONT COMPANY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIVIRUS AGENT; INDAZOLE DERIVATIVE; PROTEINASE INHIBITOR; SE 063; UNCLASSIFIED DRUG; UREA DERIVATIVE;

ANTIVIRAL ACTIVITY; ARTICLE; CHEMICAL MODIFICATION; CONTROLLED STUDY; DRUG POTENCY; DRUG SYNTHESIS; ENZYME INHIBITION; HUMAN IMMUNODEFICIENCY VIRUS 1; NONHUMAN;

HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS 1; LATEOLABRAX JAPONICUS; RNA VIRUSES;

EID: 0033571418     PISSN: 0960894X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0960-894X(99)00564-8     Document Type: Article

References (18)

1. (a) Rodgers, J. D.; Johnson, B.; Wang, H.; Greenberg, R. A.; Erickson-Viitanen, S.; Klabe, R. M.; Cordova, B. C.; Rayner, M. M.; Lam, G. L.; Chang, C-H. Bioorg Med. Chem. Lett. 1996, 6, 2919-2924.
2. (b) Rodgers, J. D.; Johnson, B. L.; Wang, H.; Erickson-Viitanen, S.; Klabe, R. M.; Cordova, B. C.; Bacheler, L. T.; Chang, C- H. Bioorg. Med. Chem. Lett. 1998, 8, 715.
3. Rodgers, J. D.; Lam, P.Y.S.; Johnson, B.L.; Wang, H.; Ko, S. S.; Seitz, S. P.; Trainor, G. L.; Anderson, P. S.; Klabe, R. M.; Bacheler, L. T.; Cordova, B. C.; Garber, S. S.; Reid, C. D.; Wright, M. R.; Chang, C-H.; Erickson-Viitanen, S. Chem. Biol. 1998, 5, 597.
4. De Lucca, G. V.; Kim, U. T.; Liang, J.; Cordova, B.; Klabe, R. M.; Garber, S.; Bacheler, L. T.; Lam, G. N.; Wright, M. R.; Logue, L. A.; Erickson-Viitanen, S.; Ko, S, S.; Trainor, G. L. J. Med. Chem. 1998, 41, 2411.
5. Simon, U.; Sus, O.; Horner, L. Liebigs Ann. Chem. 1966, 697, 17.
6. (a) Walser, A.; Flynn, T.; Mason, C. J. Heterocyclic Chem. 1991, 28, 1121.
7. (b) Zenchoff, G. S.; Walser, A.; Fryer, R. I. J. Heterocyclic Chem. 1976, 13, 33.
8. (c) Walser, A.; Zally, W. J.; Fryer, R. I. J. Heterocyclic Chem. 1974, 11, 863.
9. (a) Miyaura, N.; Suzuki, A. Chem Rev. 1995, 95, 2457.
10. (b) Ritter, K. Synthesis 1993, 735.
11. During the preparation of this manuscript, the following communication describing a Suzuki type cross coupling reaction of -iodoindazoles with aryl and heteroaryl boronic acids as a general route to -arylindazoles was published. Collot, V.; Dallemagne, P.; Bovy, P. R.; Rault, S. Tetrahedron 1999, 55, 6917.
12. 2,15%.
13. Baiocchi, L.; Corsi, G.; Palazzo, G. Synthesis 1978, 633.
14. 1H NMR, CIMS/ESIMS and HRMS/peak match) and were homogeneous by TLC.
15. The Ritonavir resistant virus contains the following five mutations: I/63P/71V/82F/84V. It was chosen for comparison purposes as significant resistance to earlier generations of cyclic ureas had been observed as noted in: Jadhav, P. K.; Ala, P.; Woerner, F. J.; Chang, C-H.; Garber, S. S.; Anton, E. D.; Bacheler, L. T. J. Med. Chem. 1997, 40, 181.
16. For the preparation of SEM protected -pyrazoleboronic acid see: Wong, M. S.; Nicoud, J-F. Tetrahedron Lett. 1993, 34, 8237.
17. i) according to the protocol described in: Erickson-Viitanen, S.; Klabe, R. M.; Cawood, P. G.; O'Neal, P. L.; Meek, J. L. Antimicrob. Agents Chemother. 1994, 38, 1628.
18. 90) according to the protocol described in: Bacheler, L. T.; Paul, M.; Jadhav, P. K.; Otto, M.; Stone, B.; Miller, J. Antiviral Chem. Chemother. 1994, 5, 111.